NVO

Peers: LLY AZN MRK PFE ABBV JNJ NVS BMY SNY AMGN

| Held by: PPH AVDE WCMI PID RODM AVIV APIE OZEM AQEC NVOH

Index	-
Market Cap	123.76B
Enterprise Value	138.32B
Income	18.19B
Sales	51.45B
Book/sh	7.66
Cash/sh	2.06
Dividend Est.	1.80 (4.87%)
Dividend TTM	1.80 (4.86%)
Dividend Ex-Date	Aug 17, 2026
Dividend Gr. 3/5Y	26.98% 19.93%
Payout	36.87%
Employees	68794
IPO	Apr 30, 1981

P/E	9.04
Forward P/E	11.08
PEG	-
P/S	2.41
P/B	4.83
P/C	17.99
P/FCF	10.49
EV/EBITDA	5.21
EV/Sales	2.69
Quick Ratio	0.66
Current Ratio	0.87
Debt/Eq	0.63
LT Debt/Eq	0.55
Option/Short	Yes / Yes

EPS (ttm)	4.09
EPS next Y	3.34
EPS next Q	0.76
EPS this Y	-7.20%
EPS next Y	-1.12%
EPS next 5Y	-0.06%
EPS past 3/5Y	26.28% 20.36%
Sales past 3/5Y	23.19% 19.21%
EPS Y/Y TTM	12.68%
Sales Y/Y TTM	13.21%
EPS Q/Q	-18.69%
Sales Q/Q	4.59%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	24.09% 11.40%

Insider Own	0.01%
Insider Trans	0.00%
Inst Own	9.87%
Inst Trans	-0.49%
ROA	21.81%
ROE	60.35%
ROIC	34.67%
Gross Margin	80.65%
Oper. Margin	45.38%
Profit Margin	35.36%
SMA20	-8.07%
SMA50	-16.31%
SMA200	-18.77%
Trades

Shs Outstand	3.35B
Shs Float	3.35B
Short Float	0.79%
Short Ratio	2.12
Short Interest	26.34M
52W High	64.16 -42.35%
52W Low	35.12 5.32%
Volatility	1.63% 1.99%
ATR (14)	1.02
RSI (14)	26.97
Beta	0.72
Rel Volume	1.13
Avg Volume	12.45M
Volume	2,855,087

Perf Week	-3.45%
Perf Month	-20.62%
Perf Quarter	-24.34%
Perf Half Y	0.22%
Perf YTD	-27.30%
Perf Year	-37.99%
Perf 3Y	-59.85%
Perf 5Y	-23.38%
Perf 10Y	81.06%
Recom	3.00
Target Price	52.40
Prev Close	37.54
Price	36.99
Change %	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-11-26	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$40
Aug-27-26	Downgrade	Deutsche Bank	Hold → Sell
Aug-12-26	Downgrade	Berenberg	Buy → Hold
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy

Show Previous Ratings

Oct-05-26 08:00AM	FDA Extends Review of Novo Nordisk Haemophilia A Treatment Denecimig (InvestorsHub)
Oct-02-26 08:13PM	Stocktwits Biotech Dealmaker Novartis, Sanofi And Novo Sign Weeks Biggest Deals (Stocktwits)
07:57PM	Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long (Stocktwits)
07:36PM	Anthropic Is Spending $100M To Build The AI Workforce It Needs For Its Next Phase (Stocktwits)
09:00AM	3 drug targets pharma is betting on next (Pharma Voice)
03:19PM	Loading…
Oct-01-26 03:19PM	How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market (Barrons.com)
09:00AM	Eli Lilly obesity drug data adds pressure on Novo Nordisk (Proactive)
08:43AM	Novo Nordisk Reports Wegovy Liver Fat Reduction in Obesity Trial Analysis (InvestorsHub)
Sep-30-26 10:59AM	Eli Lilly stock rises on striking 23% weight loss in drug combo trial (Investing.com)
10:32AM	Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects. (MarketWatch)
08:32AM	Novo Nordisk Wegovy pill weight loss switch study results (Quartz)
08:32AM	Switching to Novo Nordisk's weight loss pill helped people keep shedding pounds (Quartz)
08:27AM	Novo Nordisk Study Reports Weight Loss After Patients Switch to Oral Wegovy (InvestorsHub)
Sep-29-26 02:16PM	Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy (GuruFocus.com)
12:10PM	Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge (GuruFocus.com)
11:57AM	Loading…
11:57AM	Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data (GuruFocus.com)
08:36AM	Novo Nordisk Reports Real-World Semaglutide 2 mg Cardiovascular Analysis Versus Tirzepatide (InvestorsHub)
08:03AM	Taking Ozempic and worried about vision loss? This test can help you understand your risk. (MarketWatch)
05:45AM	Novo Nordisk strikes second licensing deal since frosty capital-markets day (MarketWatch)
01:46AM	Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal (Investing.com)
Sep-27-26 11:31PM	Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week Here Are The Stocks And Readouts To Watch (Stocktwits)
Sep-25-26 09:02PM	Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines (Stocktwits)
03:53PM	Viatris sues Novo Nordisk over generic Wegovy patent dispute (Investing.com)
10:05AM	Novo Nordisk's $1.3 Billion Deal Targets a Big Obesity-Drug Problem (GuruFocus.com)
09:56AM	Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech (GuruFocus.com)
09:50AM	Novo Nordisk signed a $1.3 billion deal for technology to make longer-lasting obesity shots (Quartz)
09:46AM	Novo Nordisk signs $1.3 billion deal for long-acting obesity shots (Quartz)
06:15AM	Novo Nordisk Licenses Nanexa Drug-Delivery Technology in Deal Worth Up to 1.17 Billion (InvestorsHub)
05:11AM	After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring (MarketWatch)
03:49AM	Nanexa shares rocket 114% on $1.3 billion Novo Nordisk licensing deal (Investing.com)
04:36PM	Loading…
Sep-23-26 04:36PM	NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day Direct US Listing Talks, Drug Approval Fail To Halt Slip (Stocktwits)
03:24PM	Novo's Oral Wegovy Just Revealed a Surprising Weight-Loss Signal (GuruFocus.com)
12:12PM	Novo Nordisk open to direct New York listing, CEO says (Proactive)
11:09AM	Huge News For Novo Nordisk Fans (GuruFocus.com)
10:52AM	European big pharma unites amid ringing alarm bells of continents dominance (Clinical Trials Arena)
08:41AM	Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets (TIKR)
07:37AM	The Stock Market Is Sleeping on the Next Big AI Catalyst (Barrons.com)
07:09AM	U.S. demand for Novo Nordisks weight loss drugs is so huge that the Danish central bank just doubled the nations entire growth forecast (Fortune)
06:10AM	Novo Nordisk CEO Says Company Open to Direct NYSE Share Listing (InvestorsHub)
Sep-22-26 10:22PM	VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data Can Viking Win Over Wegovy And Zepbound Users? (Stocktwits)
05:24PM	Novo Nordisk Just Made a Surprising Move Beyond Weight Loss (GuruFocus.com)
04:31PM	VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win (Stocktwits)
03:26PM	AstraZeneca and GSK warn Europes drug industry is at risk (The Telegraph)
02:51PM	Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch (Barrons.com)
09:49AM	Viking Therapeutics Stock Surges on Drug Trial Success (Schaeffer's Research)
09:42AM	Roche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trial (InvestorsHub)
08:22AM	Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire. (Barrons.com)
08:08AM	VKTX Stock Spikes 38% Premarket: Vikings VK2735 Shows Promise For Weight-Loss Maintenance (Stocktwits)
07:29AM	GLP-1 maker Novo Nordisk's big reveal leaves the City cold (Proactive)
06:45AM	Novo Nordisk Considers Acquisitions to Expand Weight-Loss Drug Pipeline as Competition Intensifies (InvestorsHub)
01:29AM	VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
Sep-21-26 03:49PM	LLY Stock Gains As CEO Says Foundayo Wins One-Third Of New GLP-1 Pill Starts, Breaks Ground On $6.5B Houston Plant (Stocktwits) -7.96%
03:09PM	Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round (GuruFocus.com)
11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
11:31AM	Novos Big 2030 Pitch Gets a Small Reception (Moby)
10:46AM	Novo Shares Slip as Growth Plan Disappoints Investors (Schaeffer's Research)
08:35AM	Novo Nordisk's $23B Obesity Goal Isn't Enough to Stop the Selloff (GuruFocus.com)
08:29AM	Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan (Barrons.com)
08:26AM	Novo Nordisk Shares Sink After $23 Billion Obesity Sales Target for 2030 (GuruFocus.com)
08:20AM	Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers (GuruFocus.com)
08:06AM	Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up (Reuters)
07:31AM	Novo Nordisk Targets Over Five New Blockbusters By 2030, But NVO Stock Slides On Growth Concerns (Stocktwits)
07:20AM	Novo Nordisk stock sinks after 2030 growth plan fails to impress investors (Quartz)
07:19AM	Novo Nordisk stock falls after 2030 strategy disappoints investors (Quartz)
07:13AM	Paramount shares climb on report of negotiations, and other early market movers (MarketWatch)
06:30AM	Novo Nordisk Shares Fall 6% as Drugmaker Outlines Growth Targets Through 2030 (InvestorsHub)
05:19AM	Novo Nordisk stock gets drilled on pipeline concerns its CEO sees this as the main problem (Yahoo Finance)
04:58AM	Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals (MarketWatch)
03:37AM	Stock Market Today: Dow, S&P 500 and Nasdaq set to climb as oil prices fall following U.S. statement that shipments through Hormuz at six-month high (MarketWatch)
12:37AM	Biotech Week Ahead: XLV Beats The Market Here Are The Stocks, Readouts And Events To Watch Next (Stocktwits)
Sep-19-26 10:30PM	What does the EU have that the U.S. does not? (Investing.com)
Sep-17-26 02:50PM	Novo Nordisk's hemophilia drug clears a key hurdle in Europe (GuruFocus.com)
02:33PM	NVO Stock Jumps 4% As European Committee Backs Novos Haemophilia Pen (Stocktwits)
08:31AM	Novo Nordisk Publishes Phase 3b Denecimig Results in Haemophilia A (InvestorsHub)
Sep-16-26 05:06PM	Novo Drops as Claude Enters Drug Development (GuruFocus.com)
12:33PM	Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It. (Barrons.com)
10:16AM	Novo Nordisk Scores Major AI Deal With World's Most Valuable AI Company (GuruFocus.com)
09:21AM	Novo partners with Anthropic to speed up drug development with Claude (Reuters)
09:05AM	Novo Nordisk Taps Anthropics Claude Science To Speed Up Drug Discovery Heres Everything Investors Need To Know (Stocktwits)
08:40AM	Novo Nordisk partners with Anthropic to turbocharge drug discovery (Investing.com)
08:36AM	Novo Nordisk Partners With Anthropic to Apply AI to Drug Discovery and Research (InvestorsHub)
07:59AM	Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs (Reuters)
06:44AM	NVO To Present Fresh Data From Blockbuster Wegovy Pill At European Conference As Rival Eli Lilly Readies Its Own Obesity Updates (Stocktwits)
Sep-15-26 01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive)
11:47AM	Novo Nordisk Stock Falls After Major Rebrand (GuruFocus.com)
08:15AM	Eli Lilly and Novo Nordisk have paid more than 270,000 doctors one as much as $1M to promote GLP-1 weight-loss drugs (Moneywise)
Sep-14-26 10:05PM	Novo Nordisk Rebrands as Novo': Stock Falls as Company Aims GLP-1s at Consumers (BeInCrypto)
02:47PM	Novo Nordisk Is Dropping Some Weight. It Still Faces a Bigger Challenge. (Barrons.com)
11:52AM	No more Nordisk: Novos latest trim is in its name (Pharmaceutical Technology)
09:20AM	Novo drops 'Nordisk' in corporate refresh to take on Lilly in the weight-loss wars (MarketWatch)
08:49AM	Novo Nordisk rebrands as Novo to compete in obesity market (Quartz)
08:13AM	Novo Nordisk Adopts Novo as Everyday Operating Name and Introduces New Cultural Framework (InvestorsHub)
05:13AM	Ozempic-maker Novo Nordisk slims down to 'Novo' (AFP)
04:51AM	NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To Novo Amid Another Gloomy Year (Stocktwits)
04:41AM	Novo ditches Nordisk from name as drugmaker attempts revival (Financial Times)
Sep-11-26 05:10PM	Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition (GuruFocus.com)
11:34AM	Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff (GuruFocus.com)
11:12AM	Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset (GuruFocus.com)
09:14AM	JPMorgan cautious on Hims & Hers on GLP-1 transition risk (Investing.com)
06:56AM	NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity (Stocktwits)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Executive VPMr. Karsten Munk Knudsen

PresidentMr. Maziar Mike Doustdar B.A.

EVP of R&DDr. Martin Holst Lange

EVP of PeopleMs. Tania Sabroe

Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novo Nordisk ADR

Upgrade your Finviz experience